

Datasheet: MCA87SBV440

BATCH NUMBER 100004060

Description:	MOUSE ANTI HUMAN CD45:StarBright Violet 440
Specificity:	CD45
Other names:	LCA
Format:	StarBright Violet 440
Product Type:	Monoclonal Antibody
Clone:	F10-89-4
Isotype:	IgG2a
Quantity:	100 TESTS/0.5ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species

Human

Species Cross Reactivity

Reacts with: Horse

N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form

Purified IgG conjugated to StarBright Violet 440 - liquid

Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	StarBright Violet 440	385	438

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃) 1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350
Immunogen	Human T lymphocytes.
External Database Links	<p>UniProt: P08575 Related reagents</p> <p>Entrez Gene: 5788 PTPRC Related reagents</p>
Synonyms	CD45
Fusion Partners	Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS-1 myeloma cell line.
Specificity	<p>Mouse anti Human CD45 antibody, clone F10-89-4 recognizes the human CD45 cell surface antigen, also known as the leucocyte common antigen (LCA). CD45 is a complex molecule existing in a number of isoforms.</p> <p>Antibodies recognising a common epitope on all of these isoforms are termed CD45 whilst those recognising only individual isoforms are termed CD45RA or CD45RO etc.</p> <p>Mouse anti Human CD45 antibody, clone F10-89-4 reacts with all forms of CD45 expressed by all haematopoietic cells, except erythrocytes, having a higher level of expression on lymphocytes than on granulocytes.</p> <p>Mouse anti Human CD45 antibody, clone F10-89-4 is routinely tested in flow cytometry on human peripheral blood leucocytes</p>
Flow Cytometry	Use 5ul of the suggested working dilution to label 10 ⁶ cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
References	<ol style="list-style-type: none"> 1. Dalchau, R. <i>et al.</i> (1980) Monoclonal antibody to a human leukocyte-specific membrane glycoprotein probably homologous to the leukocyte-common (L-C) antigen of the rat. Eur J Immunol. 10 (10): 737-44. 2. Quenby, S <i>et al.</i> (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Human Reprod. 14(9):2386-2391. 3. Hauser, P.V. <i>et al.</i> (2010) Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol. 177: 2011-21. 4. Mallam, E. <i>et al.</i> (2010) Characterization of <i>in vitro</i> expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler. 16: 909-18. 5. Marrinucci, D. <i>et al.</i> (2010) Cytomorphology of circulating colorectal tumor cells:a small

- case series. [J Oncol. 2010: 861341.](#)
6. Kazane, S.A. *et al.* (2012) Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. [Proc Natl Acad Sci U S A. 109: 3731-6.](#)
 7. Paul, G. *et al.* (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. [PLoS One. 7: e35577.](#)
 8. Sadarangani, A. *et al.* (2015) GLI2 inhibition abrogates human leukemia stem cell dormancy. [J Transl Med. 13: 98.](#)
 9. Gunawardene, P. *et al.* (2015) Association Between Circulating Osteogenic Progenitor Cells and Disability and Frailty in Older Persons: The Nepean Osteoporosis and Frailty Study. [J Gerontol A Biol Sci Med Sci. pii: glv190.](#)
 10. Gogoi P *et al.* (2016) Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. [PLoS One. 11 \(1\): e0147400.](#)
 11. Spaas, J.H. *et al.* (2013) Culture and characterisation of equine peripheral blood mesenchymal stromal cells. [Vet J. 195 \(1\): 107-13.](#)
 12. Gomiero, C. *et al.* (2016) Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. [Vet Res Commun. 40 \(1\): 39-48.](#)
 13. De Schauwer, C. *et al.* (2012) In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. [Cytometry A. 81 \(4\): 312-23.](#)
 14. Bianchessi, M. *et al.* (2016) Effect of Fibroblast Growth Factor 2 on Equine Synovial Fluid Chondroprogenitor Expansion and Chondrogenesis. [Stem Cells Int. 2016: 9364974.](#)
 15. Mohamed Suhaimi, N.A. *et al.* (2015) Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. [Mol Oncol. 9 \(4\): 850-60.](#)
 16. Ruiz, C. *et al.* (2015) Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. [Phys Biol. 12 \(1\): 016008.](#)
 17. Branly, T. *et al.* (2017) Characterization and use of Equine Bone Marrow Mesenchymal Stem Cells in Equine Cartilage Engineering. Study of their Hyaline Cartilage Forming Potential when Cultured under Hypoxia within a Biomaterial in the Presence of BMP-2 and TGF- β 1. [Stem Cell Rev. Jun 09 \[Epub ahead of print\].](#)
 18. GarikipatiV, N.S. *et al.* (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart. [PLoS One. 13 \(2\): e0192244.](#)
 19. Shishido, S.N. *et al.* (2019) Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. [J Transl Med. 17 \(1\): 294.](#)
 20. Welter, L. *et al.* (2020) Treatment response and tumor evolution: Lessons from an extended series of multi-analyte liquid biopsies in a metastatic breast cancer patient. [Cold Spring Harb Mol Case Stud. Nov 17 \[Epub ahead of print\].](#)

Storage	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
Guarantee	12 months from date of despatch
Acknowledgements	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
Health And Safety	Material Safety Datasheet documentation #20438 available at:

Information <https://www.bio-rad-antibodies.com/SDS/MCA87SBV440>
20438

Regulatory For research purposes only

Related Products

Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M374291:201028'

Printed on 17 Apr 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)